Introgen Therapeutics, Inc. and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company’s clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle.